Tivozanib
As of the edition of 20 October 2026, Tivozanib is a small molecule: marketed, first approved in 2017 (EU); acts on FLT1, FLT4 and KDR and 2 more; US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Fotivda
- First approved
- 24 August 2017 (EU)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- LG Chem; 2 holders in all
- Registered trials
- 39, 10 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones; Skin and connective tissue
US protection
US protection ends in 2028.
The last listed US drug-substance patent ends in 2028. The application that gives this date is held by LG Chem.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product4 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 4 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Tivozanib.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 2 |
| Phase 1 | 11 | 11 | 0 | 0 |
| Phase 2 | 21 | 9 | 4 | 8 |
| Phase 3 | 5 | 4 | 1 | 0 |
| All trials | 39 |